Optum Rx will eliminate reauthorization requirements for 40 additional medications beginning Jan. 1 as part of the company’s effort to streamline access to prescriptions.
The reductions focus on two drug classes — hormone therapy and injectables for knee osteoarthritis — and bring the total number of medications with reduced reauthorization to 180, according to a Nov. 24 news release from UnitedHealth Group, Optum Rx’s parent company. Optum Rx cut requirements for about 80 chronic disease drugs in March, followed by more than 60 additional medications in July. At the time, the company said the changes would improve access and outcomes, especially for patients with behavioral health conditions, dry eye disease, HIV and hypertension.
This initiative coincides with an expansion of PreCheck Prior Authorization, an automated tool that cuts approval time from 8.5 hours to less than 30 seconds. By Jan. 1, the platform will cover more than 45 medications and be used across 20 health systems, the release said.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
